169.97
-8.23 (-4.62%)
| Previous Close | 178.20 |
| Volume | 710,600 |
| Price / Earnings (Forward) | 64.12 |
| Price / Sales | 12.50 |
| Price / Book | 4.83 |
| 52 Weeks Range |
| Profit Margin | -3.53% |
| Operating Margin (TTM) | 5.59% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | 10.40% |
| Quarterly Earnings Growth (YOY) | 76.90% |
| Total Debt/Equity (MRQ) | 34.44% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | 145.69 M |
| Levered Free Cash Flow (TTM) | 183.66 M |
| Return on Assets (TTM) | 0.92% |
| Return on Equity (TTM) | -1.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Repligen Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.3 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 2.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.75 |
Select this tab to load the latest available analysis.
|
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 6.41% |
| % Held by Institutions | 105.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| United Capital Financial Advisors, Llc | 30 Jun 2026 | 2,790,650 |
| Maverick Capital Ltd | 30 Jun 2026 | 1,984,554 |
| Holocene Advisors, Lp | 30 Jun 2026 | 1,292,191 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |